A Phase 2A, Single Arm, Multicentre, Study of Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Who Progressed on at Least 1 Line of Systemic Therapy

Trial Profile

A Phase 2A, Single Arm, Multicentre, Study of Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Who Progressed on at Least 1 Line of Systemic Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Capecitabine (Primary) ; Varlitinib (Primary)
  • Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors ASLAN Pharmaceuticals
  • Most Recent Events

    • 08 Jan 2018 According to an ASLAN Pharmaceuticals media release, company plans to report topline data from this trial in late 2018 and, if the primary endpoint is met, subsequently submit its first regulatory filing for approval for second-line biliary tract cancer to the CFDA.
    • 08 Jan 2018 According to an ASLAN Pharmaceuticals media release, professor Shukui Qin, Chair of the Chinese Society of Clinical Oncology and Deputy Director of the Nanjing 81 Hospital, is the lead investigator for the trial.
    • 08 Jan 2018 Status changed from not yet recruiting to recruiting, according to an ASLAN Pharmaceuticals media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top